Fairmount Funds Management LLC Astria Therapeutics, Inc. Transaction History
Fairmount Funds Management LLC
- $326 Million
- Q2 2025
A detailed history of Fairmount Funds Management LLC transactions in Astria Therapeutics, Inc. stock. As of the latest transaction made, Fairmount Funds Management LLC holds 3,554,129 shares of ATXS stock, worth $23.6 Million. This represents 5.84% of its overall portfolio holdings.
Number of Shares
3,554,129
Previous 3,554,129
-0.0%
Holding current value
$23.6 Million
Previous $19 Million
0.37%
% of portfolio
5.84%
Previous 6.47%
Shares
3 transactions
Others Institutions Holding ATXS
# of Institutions
110Shares Held
49.3MCall Options Held
6.6KPut Options Held
0-
Perceptive Advisors LLC New York, NY6.49MShares$43.1 Million1.53% of portfolio
-
Vestal Point Capital, LP New York, NY4.52MShares$30.1 Million1.28% of portfolio
-
Fcpm Iii Services B.V. Naarden, P74.11MShares$27.3 Million6.34% of portfolio
-
Black Rock Inc. New York, NY3.52MShares$23.4 Million0.0% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny2.97MShares$19.7 Million0.01% of portfolio
About Astria Therapeutics, Inc.
- Ticker ATXS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 15,178,000
- Market Cap $101M
- Description
- Astria Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare and niche allergic, and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in preclinical development stage...